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OMNIgene SPUTUMAbstract This preliminary study evaluated the transport reagent OMNIgene SPU-
TUM (OMS) in a real-world, resource-limited setting: a zonal hospital and national
tuberculosis (TB) reference laboratory, Nepal. The objectives were to: (1) assess
the performance of OMS for transporting sputum from peripheral sites without cold
chain stabilization; and (2) compare with Nepal’s standard of care (SOC) for
Mycobacterium tuberculosis smear and culture diagnostics. Sixty sputa were manu-
ally split into a SOC sample (airline-couriered to the laboratory, conventional pro-
cessing) and an OMS sample (OMS added at collection, no cold chain transport or
processing). Smear microscopy and solid culture were performed. Transport was
0–8 days. Forty-one samples (68%) were smear-positive using both methods. Of
the OMS cultures, 37 (62%) were positive, 22 (36%) were negative, and one (2%)
was contaminated. Corresponding SOC results were 32 (53%), 21 (35%), and seven
(12%). OMS “rescued” six (i.e., missed using SOC) compared with one rescue using
SOC. Of smear-positives, six SOC samples produced contaminated cultures whereas
only one OMS sample was contaminated. OMS reduced culture contamination from
12% to 2%, and improved TB detection by 9%. The results suggest that OMS could per-
form well as a no cold chain, long-term transport solution for smear and culture
testing. The findings provide a basis for larger feasibility studies.
 2016 Ministry of Health, Saudi Arabia, Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).
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TheWorld Health Organization’s End TB Strategy [1]
calls for universal access to drug susceptibility
testing and systematic screening of contacts and
high-risk groups, and identifies these elements as
essential to eliminating Mycobacterium tuberculo-
sis (MTB) infections. To achieve these targets, it is
necessary to consider how sample transportation
affects patient access to drug-susceptibility tests
and how sample quality affects test results. An
increasing amount of pressure is being placed on
countries to test more samples using an expanding
list of techniques; however, constraints differ by
setting andminimal attention has been paid to prac-
tical solutions that: (1) improve sample quality; and
(2) provide a flexible approach that functions seam-
lessly with established and novel diagnostic tests.
Such solutions are critical to enable high-priority,
resource-constrained countries to scale their tuber-
culosis (TB) testing programs.
The National TB Program in Nepal has mounted
one of the most successful TB campaigns in Asia,
an effort that increased the rate of successful TB
treatment outcomes from 45% in 1990 to 90% by
2010 [2]. However, Nepal faces an increasing
threat from multidrug-resistant TB, and faces
tremendous challenges transporting samples from
peripheral hospitals to a centralized testing labora-
tory [2]. Remote collection sites can be as far as
400 km away from the country’s two TB reference
laboratories in the capital city Kathmandu, and
Nepal’s mountainous geography can delay sample
transport by up to 6 days. Currently, long-term
transport and storage of sputum samples typically
requires reliable and continuous access to refriger-
ation to maintain sample integrity at the level
required for smear, culture, and molecular TB
diagnostics [3]. Constraints on sputum sample
transportation increase the costs associated with
each patient diagnosis, and inadequate sample
preservation during transit can result in multiple
diagnostic and therapeutic issues: culture contam-
ination; invalid test results; need for repeated
patient sampling (with inherent delays to reaccess
patients/collection sites and transport each sam-
ple); and, consequently, significant delays in initi-
ating effective treatment. These constraints have
led to a challenging transport situation for Nepal.
Whereas the country’s standard operating guideli-
nes state that samples should be transported
within 3 days, the transport process routinely takes
4 or more days, and cold chain stabilization is not
feasible due to high courier costs and the require-
ment for reference laboratories to return coldboxes to peripheral laboratories. National TB con-
trol programs need products that can help effec-
tively scale their testing networks while
maintaining established diagnostic algorithms and
workflows. OMNIgene SPUTUM (OMS; DNA Genotek,
Ottawa, ON, Canada) is a novel sample transport
reagent that decontaminates and liquefies sputum,
that is compatible with all gold standard TB tests
(e.g., smear microscopy, solid and liquid culture,
Cepheid GeneXpert, Hain Lifescience line probe
assay) and other molecular assays [4], and that
does not require cold chain. Versatile, reliable,
diagnostically beneficial products that can be
easily integrated into laboratory systems can offer
a variety of solutions for TB control programs: cost
reduction; increased patient access to reliable
tests; improved sample quality for testing; and
more rapid administration of appropriate therapy
leading to better patient outcomes.
According to the World Health Organization
guidelines, sputum samples must be refrigerated
if they are stored or transported more than 24 h
prior to testing [5]; however, it is widely known
that many resource-limited countries cannot
finance or logistically provide reliable cold chain
transport. The aim of this preliminary study was
to evaluate the effectiveness of OMS in a real-
world setting and to determine the feasibility of
conducting additional larger studies. Performance
of OMS was compared with that of Nepal’s current
standard sputum collection, shipping, and process-
ing protocol with respect to results for smear
microscopy and solid MTB culture.
2. Materials and methods
2.1. Sample collection and transport
methods
The study was conducted at the GENETUP TB Ref-
erence Laboratory in Kathmandu, Nepal in Febru-
ary and March 2015. Sixty raw sputum samples
were collected from suspected TB patients at
peripheral hospitals. An individual sterile swab
stick was used to manually split each sample into
two equivalent portions as it was poured from
one container to another. Portions were randomly
assigned to one treatment method prior to being
packaged for transport. As per the standard proce-
dures for sputum collection, shipping, and process-
ing in Nepal, one sample portion [hereafter
referred to as the “standard of care (SOC) sample”]
was left untreated. The second sample portion (the
“OMS sample”) had an equal volume of OMS
reagent added to it at the time of collection. All
Sputum transport solution and routine TB testing 259samples were shipped via airline courier and with-
out refrigeration. (Note that cold chain stabiliza-
tion is not required for OMS samples. Although
cold chain transport is the recommended standard
for sputum samples collected in Nepal, this was not
feasible due to the high cost associated with this
transport method.) Transport times varied from
0 days to 8 days depending on the distance from
the collection site to the GENETUP laboratory.
Temperatures during transport ranged from 4 C
to 24 C, as recorded in Kathmandu during the
study period.
2.2. Sample processing and testing
Upon arrival at the laboratory, each SOC sample
was processed using the Nepal standard NaOH/N-
acetyl L-cysteine (NALC) method: fresh prepara-
tion of a 4% NaOH, 2.9% trisodium citrate, 0.5 g
NALC solution, addition of an equal volume of solu-
tion to the sample, and 15 min of incubation at
room temperature, followed by neutralization
using sterile phosphate buffer and centrifugation
to produce a sediment. The OMS sample required
no further processing and was directly centrifuged
to produce a sediment.
Sediments were resuspended in sterile phos-
phate buffer and were assessed by smear micro-
scopy and cultured on Lowenstein–Jensen slants
in duplicate. Cultures were incubated at 37 C for
up to 56 days. Smears were categorized as negative
or as one of four levels of acid-fast bacilli detec-
tion: scanty, 1+, 2+, or 3+.
2.3. Data collected and analysis
Transport times from collection site to laboratory
were recorded. For each OMS sample and SOC sam-
ple, smear results were reported as negative or
positive (defined as scanty, 1+, 2+ or 3+). Culture
results were reported as negative, positive (i.e.,
growth), or contaminated. For positive cultures,
the interval from date of inoculation to date of
observable growth (i.e., time to culture-positive
status) was recorded in days. When the duplicate
culture slants from a sample yielded discrepant
results, a single outcome was reported as follows:
samples that yielded one contaminated and one
negative culture were counted as negative; sam-
ples that yielded one contaminated and one posi-
tive culture were counted as positive; and
samples that yielded two contaminated cultures
were counted as contaminated.
The OMS and SOC methods were compared with
respect to proportions of TB cases detected by
smear and by culture, respectively, and withrespect to proportions of contaminated cultures.
In addition, average time to culture-positive status
(in days) was compared for the two methods. Find-
ings were compared relative to transport time, as
appropriate.3. Results
Table 1 summarizes transport times and key diag-
nostic information and results of each of the 60
respective pairs of OMS and SOC samples. Trans-
port times ranged from 0 days to 8 days. Sputum
volumes ranged from 0.5 mL (n = 2) to 4.5 mL,
and the majority (n = 50) were P2 mL. Of the 60
sputum samples collected, 41 (68% of total) were
positive by smear microscopy with OMS and SOC,
respectively. There were two discrepancies
between the methods: Sample 1945 for which only
the OMS portion was positive, and Sample 2287 for
which only the SOC portion was positive. Both sam-
ples were graded as scanty by smear microscopy.
The impact of OMS on smear microscopy was
negligible, as smear categorization was similar for
the two methods. Note that low-positive sputum
samples (i.e., those categorized as scanty or 1+)
were not negatively affected by transport in OMS,
even after 7 days in transit (Table 1).
Regarding culture results, of the 60 OMS sam-
ples, 37 (62%) were culture-positive, 22 (36%) were
culture-negative, and one culture (2% of total) was
contaminated (Fig. 1). In contrast, 32 (53%) of the
60 SOC samples were culture-positive, 21 (35%)
were culture-negative, and seven (12%) of the
SOC cultures were contaminated (Fig. 1).
Overall average time to culture-positive was not
significantly affected by treatment method
(23 days for both treatment methods; Table 1,
Fig. 1). The largest variation in time to culture-
positive was observed in samples that were 2 days
in transport. In this group, the OMS-treated sam-
ples took an average of 4 days longer to become
culture-positive (range, 16–23 days) compared
with the SOC-treated samples (range, 16–18 days;
Table 1). However, only five samples were trans-
ported for 2 days and each treatment method had
80% detection. When numbers of culture positives
per group were compared relative to transport
time, the OMS group had two more positives at
3 days and 4 days of transport, and one more posi-
tive at 5 days of transport; the other transport cat-
egory comparisons were identical.
For analysis, “rescued” was used to indicate
instances where one portion of a sample (i.e.,
OMS or SOC) was identified MTB-positive or MTB-
negative by culture, whereas the corresponding
Table 1 Summary of transport time and diagnostic results for the OMNIgene SPUTUM and standard of care methods.
Sample ID Days in
transport
Smear LJ culture: time to positive
(d)
OMS impact
on TTP (d)
Avg TTP SOC Avg TTP OMS D TTP for OMS
SOC OMS SOC OMS
4600 0 1+ 1+ 21 24 3 21 24 3
4796 0 Neg Neg NG NG NG
4820 0 Neg Neg NG NG NG
4547 0 Neg Neg NG NG NG
4582 0 Neg Neg NG NG NG
4649 0 Neg Neg NG NG NG
4671 0 Neg Neg NG NG NG
4661 0 Neg Neg NG NG NG
4817 0 Neg Neg NG NG NG
2081 2 2+ 1+ 17 23 6 17 21 4
2071 2 2+ 1+ 17 23 6
2336 2 3+ 3+ 16 16 0
2366 2 2+ 2+ 18 23 5
2374 2 1+ Scanty NG NG NG
1966 3 2+ 1+ Contaminated 28 Rescued 22 23 1
2064 3 1+ Scanty 25 25 0
2067 3 1+ 3+ 36 29 –7
2068 3 1+ 1+ Contaminated/29 25 –4
2093 3 1+ 1+ 6 19 13
2099 3 3+ 2+ 25 19 –6
2114a 3 2+ 1+ Contaminated 23 Rescued
2186 3 Neg Neg NG NG NG
2200 3 3+ 3+ 12 18 6
2355 3 Neg Neg Contaminated NG NG/Rescued
2356 3 Neg Neg NG NG NG
2357 3 Neg Neg NG NG NG
2360 3 Neg Neg NG NG NG
2370 3 Neg Neg NG NG NG
2371a 3 Neg Neg NG NG NG
2372 3 3+ 3+ 18 18 0
1872 4 2+ 3+ 16 23 7 22 22 0
1879 4 1+ 1+ Contaminated/NG NG NG
1880 4 3+ 3+ 16 25 9
2054 4 3+ 2+ Contaminated 34 Rescued
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2060 4 3+ 2+ 18 18 0
2062 4 2+ Scanty 29 25 –4
2075 4 2+ 1+ 29 18 –11
2105 4 2+ 2+ Contaminated/23 17 –6
2117 4 3+ 1+ Contaminated 14 Rescued
2183 4 Neg Neg NG NG NG
1911 5 1+ 1+ 25 25 0 28 28 0
1929 5 Scanty Scanty NG NG NG
1941 5 Neg Neg NG NG NG
1945 5 Neg Scanty 33 42 9
1946 5 1+ 2+ 41 41 0
2007 5 1+ Scanty 28 37 9
2014 5 3+ 3+ 25 21 –4
2027 5 1+ 1+ 37 28 –9
2034 5 1+ Scanty 21 25 4
2167 5 3+ 3+ 19 19 0
2165 5 3+ 3+ Contaminated 19 Rescued
2326 5 1+ 2+ 25 20 –5
1932 6 Neg Neg NG NG NG 19 18 –1
2038 6 3+ 3+ 18 22 4
2287 6 Scanty Neg NG NG NG
2289 6 1+ 2+ 26 Contaminated Missed
2292 6 3+ 3+ 14 17 3
2307 6 2+ 1+ 16 16 0
2181 7 1+ 1+ 21 21 0 21 21 0
2244 8 3+ 3+ Contaminated 21 Rescued n/a 21 n/a
Avg = average; d = days; LJ = Lowenstein–Jensen; Neg = negative; NG = no growth after 56 days; OMS = OMNIgene SPUTUM; SOC = standard of care; TTP = time to culture-positive;
D TTP = difference in TTP between the methods.
a Collected sample volume was 0.5 mL.
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Fig. 1 Comparison of OMNIgene SPUTUM and standard of care: solid culture results overall.
262 B. Maharjan et al.portion yielded no usable diagnostic results (i.e., a
contaminated culture, which provides neither a
negative nor a positive result). Use of the OMS
method resulted in seven samples being rescued
(i.e., seven additional actionable results that
would have been missed using SOC alone) and one
sample being “missed” (i.e., for 1 of the 60 total
samples, the culture for the SOC portion was posi-
tive whereas the culture for the OMS portion was
contaminated). In contrast, the SOC method
missed seven positives and rescued one sample
(Table 1, Fig. 1).
Of the smear-positive samples (i.e., 41 total for
each method), the proportions identified as0 
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Fig. 2 Comparison of OMNIgene SPUTUM and standard of cculture-positive for MTB were 90% (n = 37) for the
OMS method and 76% (n = 31) for the SOC method.
Within the smear-positive subgroup, the numbers
of culture-negative results with the two methods
were comparable; however, there were more con-
taminated cultures with the SOC method (i.e., 6
for SOC vs. 1 for OMS; Fig. 2).
Within the smear-negative subgroup, the OMS
treatment method identified 19 samples as
culture-negative, while the SOC treatment method
identified 17 culture-negative, one culture-
positive, and one culture-contaminated. Two dis-
crepant smear microscopy results were identified:
Sample 1945 was smear-positive for OMS only and23
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Sample 1945 was culture-positive for both methods
(average times to culture-positive: 33 days and
42 days for SOC and OMS, respectively), while Sam-
ple 2287 was culture-negative for both methods.
One smear-negative sample was rescued by OMS
treatment. Sample 2355 was culture-negative
(i.e., an actionable diagnostic result) following
OMS treatment, but was culture-contaminated
(i.e., an unusable diagnostic result) after SOC
treatment (Table 1 and Fig. 3).
4. Discussion
This evaluation showed that using the OMS reagent
at point of collection might improve diagnostic
results and reduce the complexity associated with
SOC methods. The study demonstrated positive
impacts on several key endpoints: (1) costs, OMS
decreased culture contamination rates, thus
potentially reducing the expense of repeat testing;
(2) improved workflow, OMS ensured the highest
quality sputum samples even after 8 days of trans-
port at ambient temperature, eliminated the need
for daily preparation of NaOH/NALC, and simplified
laboratory processing procedures; and (3)
improved TB case detection, OMS yielded a greater
proportion of MTB-positive test results. Most
importantly, in seven cases, the samples treated
with the OMS reagent yielded usable diagnostic
results, whereas the corresponding samples trea-
ted with the SOC method resulted in the need for
a second sputum collection to enable repeat test-
ing by culture. This difference has significant impli-
cations for patient care, as patients may be lostduring follow up, and repeat collection and retest-
ing will delay the initiation of appropriate antibi-
otic therapy [6].
OMS offers several key advantages over the spu-
tum collection and processing method currently
used in Nepal. The OMS reagent is a highly stable
product (1 year shelf life) that requires no addi-
tional preparation in the laboratory. This means
that capturing efficiencies through task shifting of
technician time would be easily achievable. Fur-
ther, the ability to add the reagent at the point
of collection helps ensure that the highest quality
sample is received by the laboratory, because the
product reduces putrefaction and downstream cul-
ture contamination rates. Maintaining sample
integrity facilitates accurate and timely TB diagno-
sis, which is critical for countries that are imple-
menting large-scale testing networks.
This study identified another advantage of the
OMS reagent; it allows samples to be transported
for extended periods of time without the need
for cold chain. This could significantly reduce costs
associated with sample transport [7] and could sim-
plify TB testing algorithms for countries with
remote populations that, prior to this advance-
ment, have been difficult to access for testing
due to sample transportation challenges [8]. In
addition to markedly facilitating transport and
maintaining sample integrity, samples prepared
using OMS are easily integrated into existing diag-
nostic workflows without the need for costly infras-
tructure investment or retooling of established
laboratory methods. As the present study indi-
cates, sediments from OMS-treated sputa are
amenable to smear microscopy and solid culture
264 B. Maharjan et al.methods. Other sputum decontamination solutions
have been evaluated as either laboratory-added
reagents [9] or transport alternatives [10], but
these products have limitations related to shelf-
life stability or compatibility with liquid culture
systems. We have previously demonstrated that
OMS is stable for 1 year prior to use and is compat-
ible with a broad range of additional diagnostic
methods, including liquid culture (Mycobacteria
Growth Indicator Tube, Becton Dickinson and Com-
pany, Franklin Lakes, NJ, USA) [4], Cepheid GeneX-
pert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA)
[11], Hain Lifescience line probe assays (Hain Life-
science, Nehren, Germany) [12], and other molec-
ular applications [11]. Further, the versatility and
fundamental sample preservation features of the
OMS method lend it not only to the latest current
diagnostic advancements for TB, but also to test
platforms that will be developed and used in the
foreseeable future.
Minor differences were observed between the
OMS and SOC methods with respect to smear cate-
gorization and time to culture-positive, and these
likely reflect the imprecision of manually splitting
a complex biological sample in half prior to lique-
faction. The study had limitations: (1) manually
splitting sputum samples can lead to uneven distri-
bution of bacilli, which is of particular importance
with low-positive samples; (2) a considerable num-
ber of samples that were identified as MTB-
negative (by smear and culture) had required no
transport prior to testing (i.e., 9/10 samples with
0 days in transport were negative on both diagnos-
tic tests; Table 1); and (3) most samples underwent
3–5 days of transport, whereas only a small num-
ber of samples underwent prolonged transit (7 days
or 8 days). The higher-than-expected proportion of
culture-negative results for smear-negative sam-
ples was most likely an artifact of sample splitting,
which would have the greatest impact on samples
with negative or scanty smear grades. Additional
studies will be required to further evaluate this
reagent in different regional settings; however,
extended transport in OMS (i.e., longer than
4 days) demonstrated that this reagent performed
better than Nepal’s SOC method in ensuring the
integrity of sputum samples for culture, as two of
the six OMS-rescued samples were in this
transport-time category.
5. Conclusion
Challenges with long-term transport of sputum
samples from peripheral sites to a centralized lab-
oratory include high cost and logistics of providingcold chain stabilization, loss of samples through
putrefaction, reduced case detection due to loss
of viable MTB, and high rates of culture contamina-
tion. These issues exacerbate delays in reporting
clinically relevant results to the clinician, and they
can impact a patient’s health when repeat testing
is required prior to initiating antibiotic therapy.
Our preliminary findings from this in-country
study suggest that OMS could negate or substan-
tially mitigate key challenges associated with tra-
ditional sputum sample transport. Compared with
the SOC method in Nepal, transporting samples in
OMS reduced culture contamination rates from
12% to 2%, and improved detection of MTB-
positive patients by 9%. The results suggest that
OMS performs well at maintaining sample integrity
for smear and solid culture, and has potential as an
easy-to-implement solution that could reduce costs
of testing (at the laboratory and national program
levels) and improve patient access to timely results
and clinical decision-making. Future investigations
with larger sample sizes will be valuable, and will
ideally include testing via liquid culture, testing
smear-negative sputa with extended transport,
and analysis of cost savings.
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